Impact of Low Skeletal Muscle Mass on Complications and Survival for Gastric Cancer: A Propensity Score Matching Analysis

Zhen Fang
Shandong Provincial Hospital

Peijuan Li
First Affiliated Hospital of Dalian Medical University

Jin Liu
Shandong Provincial Hospital

Wei Chong
Shandong Provincial Hospital

Fengying Du
Shandong Provincial Hospital

Hao Wu
Shandong Provincial Hospital

Yang Liu
Shandong Provincial Hospital

Jiongdi Lu
Beijing Xuanwu Hospital: Xuanwu Hospital

Fei Li
Beijing Xuanwu Hospital: Xuanwu Hospital

Liang Shang
Shandong Provincial Hospital

Leping Li (✉ lileping@medmail.com.cn)
Shandong Provincial Hospital https://orcid.org/0000-0003-2329-6791

Research Article

Keywords: Gastric Cancer, Psoas muscles index (PMI), Prognosis, Propensity Score Matching Analysis

DOI: https://doi.org/10.21203/rs.3.rs-614857/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** Increasing evidence has indicated that low skeletal muscle mass is linked with cancer prognosis, but existing have shown contrasting results. The purpose of the study is to determine the impact of preoperative low skeletal muscle mass (LSMM) on complications and survival of patients who undergo laparoscopic gastrectomy for gastric cancer (GC).

**Methods:** Patients who undergo laparoscopic gastrectomy for GC were enrolled and third lumbar vertebra psoas muscles index (PMI) was assessed by computer tomography (CT). Using propensity score matching (1:1) to obtain 2 well-balanced cohorts for available variables influencing clinical outcomes, comparing the postoperative complications and 3-year overall survival (OS) between LSMM group and non-LSMM group.

**Results:** A total of 386 patients, 226 were matched for analyses. Compared with the non-LSMM group, the LSMM group manifested significantly shorter 3-year OS (58.14% vs 71.95%, \( P=0.034 \)). However, the incidence of postoperative complications was no difference between two groups after matching. After stratification based on the pT stage of the tumor, statistically significant difference in the 3-year OS rates of the advance GC cohort between the two groups were observed.

**Conclusions:** LSMM predicts a poor prognosis for patients with advance GC and it is not associated with postoperative complications.

**Background**

Gastric cancer (GC) is one of the most common gastrointestinal malignancies worldwide. According to the latest global cancer statistics, GC is the 5th most common malignant tumor and the 4th leading cause of cancer-related mortality[1–3]. Gastrectomy is the most effective treatment for GC. With the rapid development of minimally invasive surgery, laparoscopic gastrectomy has become the first choice for the treatment of GC without metastasis. However, it is associated with the occurrence of postoperative complications, tumor recurrence and even death[4, 5].

Skeletal muscle depletion initially defined as the progressive loss of skeletal muscle mass as a result of the aging process[6]. Recently, it has garnered much attention because of its association with adverse outcomes in cancer patients, such as postoperative complications, poor prognostic, and death[7–12]. However, we still did this study for the following reasons: ①The conclusion of the present study is not consistent. ②At present, there is no study to analyze the relationship between skeletal muscle mass and postoperative outcome by using Propensity Score Matching (PSM). ③There are some new findings in the study.

Propensity score analysis is a statistical technique commonly used to evaluate the efficacy of clinical interventions in observational studies[13]. Propensity score matching (PSM) is to match individuals with the same or similar propensity scores in the control group and the treatment group, so as to balance the covariates between the groups and reduce the selection bias of the treatment group. The propensity scoring method can make observational research achieve the effect of randomization without excessive stratification and over-matching. PSM can provide more reliable evidence. So far, there is no research using PSM to analyze the relationship between skeletal muscle mass and the outcome of GC after gastrectomy.
In this study, we focused on skeletal muscle mass by measuring bilateral psoas muscles mass using computed tomography (CT) scan before surgery. The primary aim of the study was to ascertain the effect of preoperative low skeletal muscle mass (LSMM) on postoperative complications and OS rate via using PSM.

**Materials And Methods**

**Patients**

Patients who underwent laparoscopic gastrectomy for primary GC at our hospital between January 2017 and December 2018 were enrolled in this retrospective study. The inclusion criteria: patients who were pathologically diagnosed as primary GC; patients who were administrated for the primary diagnosis and were therapy naive; patients who were performed laparoscopic gastrectomy. Patients were excluded if they had chemoradiotherapy, targeted therapy before surgery; they had identified metastasis before surgery; CT examination was not performed within 15 days before surgery; their clinical data and follow-up data were incomplete or non-detailed. The study was approved by the Ethics Committee of Shandong Provincial Hospital.

**Data Acquisition**

All relevant data were retrospectively collected from the hospital database, including age, sex, body mass index (BMI), nutrition risk screening 2002 (NRS2002), tumor grade, TNM stage, albumin, total protein, hemoglobin, lymphocyte percentage (LYM%), platelets, white blood cell (WBC), type of resection, comorbidities and 1-, 3-year follow-up records.

**Skeletal Muscle Mass Analysis**

Computed tomography (CT) images of the third lumbar vertebra level, used to assess psoas muscle mass. To calculate the PMI, bilateral psoas muscles mass assessed by CT scan is divided by the square of the patient's height. LSMM was accepted when the PMI was $6.36\, \text{cm}^2/\text{m}^2$ or less for men and $3.92\, \text{cm}^2/\text{m}^2$ or less for women (cut-off values determined in Asian populations[14]). All CT images were analyzed by two trained observers. The reader was blinded to each patient's diagnosis and clinical state.

**Variables and definitions**

According to the international classification of gastric cancer, early gastric cancer is defined as a lesion confined to the mucosa or submucosa and presence or absence of regional lymph node metastasis, while advanced gastric cancer is defined as T2-T4 cancer without distant metastasis. TNM staging was based on the American Joint Committee on Cancer (AJCC) 8th edition. In the study, postoperative complications were defined as surgical related adverse events within 30 days after surgery.

**Statistical Analysis**

The statistical analyses were performed using IBM SPSS Statistics 26 and R software version 3.5.3 in this study. Continuous variables were presented as mean ± standard deviation (SD). Continuous variables were compared between groups using the independent t test or Mann-Whitney U test. Categorical variables were analyzed by χ2 test or Fisher's exact test. Patients in the cohorts of LSMM and non-LSMM were propensity score-matched at a 1:1 ratio using the Nearest Neighbor Matching approach with a caliper = 0.2. Propensity Score Matching based on age, preoperative BMI, albumin, NRS2002, LYM%, WBC. Kaplan–Meier method and Log-rank test were
performed to conduct survival analyses and evaluate differences in survival time, respectively. Values of $P < 0.05$ were considered statistically significant. The assessment of propensity score matching is also shown (Supplemental Fig. 1).

**Results**

**Population**

From January 2017 to December 2018, 386 patients were enrolled and 789 were excluded in the study. Figure 1 is a flow diagram describing the patient selecting and matching process.

**Comparison of the clinical and pathological data between the LSMM and non-LSMM groups before and after propensity score matching**

Patients’ demographic characteristics and clinical features are listed in Table 1. Before propensity-matching, there were statistically significant differences in the age ($P < 0.0001$), BMI ($P < 0.0001$), NRS2002 ($P < 0.0001$), albumin ($P < 0.0001$), LYM% ($P = 0.01$) and WBC ($P = 0.006$) between the two groups, but no significant differences were observed in the sex, tumor histological grade, pT Stage, pTNM Stage, comorbidities or type of resection (all $P > 0.05$) (Table 1). After the propensity score matching ratio was set to 1:1, the clinical and pathological data of 113 patients in the LSMM group were found comparable with 113 patients in the non-LSMM group ($P > 0.05$ between all variables) (Table 1).
| Parameter          | Before Propensity-matching | P Value | After Propensity-matching | P Value |
|-------------------|----------------------------|---------|---------------------------|---------|
|                   | LSMM(n = 249)              |         | LSMM(n = 113)             |         |
|                   | non-LSMM(n = 137)          |         | non-LSMM(n = 113)         |         |
| Age (yr)          | 59.47 ± 9.53               | <0.0001 | 55.42 ± 9.67              | 0.505   |
| Sex               |                           | 0.736   |                           | 0.656   |
| Male              | 187(75.1%)                 | 0.309   | 80(70.8%)                 | 0.421   |
| Female            | 62(24.9%)                  | 0.237   | 33(29.2%)                 | 0.894   |
| BMI (kg/m²)       | 23.37 ± 2.55               | <0.0001 | 24.46 ± 2.35              | 0.656   |
| Smoker            | 117(46.99%)                | 0.039   | 52(46.02%)                | 0.421   |
| Drinker           | 108(43.37%)                | 0.237   | 51(45.13%)                | 0.894   |
| NRS 2002 score    |                           | <0.0001 |                           | 0.89    |
| <3                | 117(46.99%)                | 0.184   | 4(3.54%)                  | 0.748   |
| ≥ 3               | 132(53.01%)                | 0.495   | 41(36.28%)                |         |
| Comorbidities     |                           |         |                           |         |
| Hypertension      | 52(20.88%)                 | 0.128   | 21(18.58%)                | 0.152   |
| Diabetes          | 30(12.05%)                 | 0.607   | 12(10.62%)                | 0.538   |
| Chronic kidney disease | 15(6.02%) | 0.495   | 8(7.08%)                  | 0.789   |
| Chronic lung disease | 22(8.84%) | 0.184   | 4(3.54%)                  | 0.748   |
| Tumor grade       |                           | 0.772   |                           |         |
| I-I               | 80(32.13%)                 | 0.384   | 43(17.27%)                | 0.597   |
| I                 | 169(67.87%)                |         |                           |         |
| TNM Stage         |                           | 0.214   |                           | 0.69    |
| Stage I-II        | 109(43.78%)                | 0.548   | 54(47.79%)                |         |
| Stage III         | 140(56.23%)                | 0.59    | 56(49.56%)                |         |
| Type of resection |                           | 0.384   |                           | 0.597   |
| Total gastrectomy | 43(17.27%)                 | 0.384   | 43(17.27%)                | 0.597   |
| Subtotal gastrectomy | 206(82.73%) | 0.384   | 206(82.73%)               | 0.597   |

NRS 2002: nutrition risk screening 2002; BMI: body mass index; LSMM: low skeletal muscle mass
## Parameter | Before Propensity-matching | P Value | After Propensity-matching | P Value
--- | --- | --- | --- | ---
### Laboratory indicators
| Parameter | LSMM (n = 249) | non-LSMM (n = 137) | | LSMM (n = 113) | non-LSMM (n = 113) |
|--- | --- | --- | --- | --- | --- |
| Albumin (g/L) | 40.40 ± 4.18 | 42.15 ± 4.34 | <0.0001 | 41.39 ± 4.16 | 41.75 ± 4.12 | 0.529 |
| Total protein (mg/L) | 66.75 ± 5.24 | 67.78 ± 6.54 | 0.114 | 67.69 ± 5.30 | 67.38 ± 6.71 | 0.704 |
| Hemoglobin (g/L) | 131.29 ± 21.48 | 133.36 ± 22.48 | 0.375 | 133 ± 22.12 | 132.83 ± 22.79 | 0.955 |
| Lymphocytes (×10⁹/L) | 1.64 ± 0.55 | 1.66 ± 0.46 | 0.685 | 1.63 ± 0.55 | 1.67 ± 0.47 | 0.532 |
| Lymphocytes (%) | 28.91 ± 9.20 | 31.13 ± 7.33 | 0.01 | 30.48 ± 9.23 | 30.52 ± 7.11 | 0.964 |
| Platelets (×10⁹/L) | 249.48 ± 75.61 | 246.33 ± 62.04 | 0.677 | 245.12 ± 70.10 | 245.33 ± 61.96 | 0.982 |
| WBC (×10⁹/L) | 5.88 ± 1.71 | 5.45 ± 1.29 | **0.006** | 5.48 ± 1.50 | 5.56 ± 1.32 | 0.695 |

NRS 2002: nutrition risk screening 2002; BMI: body mass index; LSMM: low skeletal muscle mass

### Univariate and multivariate analysis of risk factors for postoperative complications

The distribution of postoperative complications is listed in Table 2. Univariate and multivariate analysis identified the following as prognostic factors for postoperative complications: albumin (P = 0.036), hemoglobin (P = 0.03), smoker (P = 0.014). There were no statistically significant differences in the complications between the LSMM group and non-LSMM group after propensity score matching (P = 0.654). (Table 3)
Table 2
Postoperative complications between patients with LSMM or non-LSMM

| Parameter                                    | Before Propensity-matching | After Propensity-matching |
|----------------------------------------------|----------------------------|---------------------------|
|                                              | LSMM(n = 249) | non-LSMM(n = 137) | LSMM(n = 113) | non-LSMM(n = 113) |
| All complications                            |               |                   |               |                   |
| Infectious complications                     |               |                   |               |                   |
| Incision infection                           | 4             | 3                 | 2             | 3                 |
| Intra-abdominal abscess                      | 6             | 0                 | 2             | 0                 |
| Pneumonia                                    | 17            | 5                 | 7             | 5                 |
| Noninfectious complications                  |               |                   |               |                   |
| Anastomotic leakage                          | 7             | 1                 | 0             | 1                 |
| Duodenal stump leakage                       | 2             | 0                 | 0             | 0                 |
| Chylous ascites                              | 2             | 0                 | 0             | 0                 |
| Gastrointestinal obstruction                 | 6             | 1                 | 1             | 1                 |
| Bleeding                                     | 2             | 0                 | 0             | 0                 |
Table 3
Univariate and multivariate analysis of risk factors for postoperative complications

| Parameter      | Categories | Complications | Univariate analysis | Multivariate analysis |
|----------------|------------|---------------|---------------------|-----------------------|
|                |            | Yes (n = 22)  | No (n = 204) OR     | 95% CI                | P-Value OR | 95% CI | P-Value |
| Sex            | Male       | 18            | 145                 | 1.832                 | 0.595–5.650 | 0.286 |
|                | Female     | 4             | 59                  | Reference             |            |        |         |
|                |            |               |                     |                       |            |        |         |
| Age (yr)       |            | 53.55 ± 8.25  | 55.14 ± 10.02       | 0.472                 |            |        |         |
| LSMM           | Yes        | 12            | 101                 | 1.224                 | 0.506–2.959 | 0.654 | 0.922 | 0.291–2.923 | 0.89 |
|                | No         | 10            | 103                 | Reference             | Reference |        |         |
| BMI (kg/m²)    |            | 25.29 ± 2.41  | 24.45 ± 2.51        | 0.138                 | 0.456          |        |         |
| NRS 2002       | ≥ 3        | 22            | 59                  | <0.0001               | 0.995          |        |         |
|                | <3         | 0             | 145                 | Reference             |            |        |         |
| Drinker        | Yes        | 10            | 93                  | 0.995                 | 0.411–2.406 | 0.99  |        |         |
|                | No         | 12            | 111                 | Reference             | Reference |        |         |
| Smoker         | Yes        | 15            | 83                  | 3.124                 | 1.221–7.994 | 0.013 | 4.111 | 1.328–12.720 | 0.014 |
|                | No         | 7             | 121                 | Reference             | Reference |        |         |
| Diabetes       |            | 2             | 25                  | 0.716                 | 0.158–3.250 | 0.653 |        |         |
|                |            | 20            | 179                 | Reference             |            |        |         |
| Tumor grade    | I-II       | 16            | 135                 | 1.363                 | 0.510–3.639 | 0.535 |        |         |
|                | I           | 6             | 69                  | Reference             |            |        |         |
| T Stage        | Early      | 4             | 54                  | 0.617                 | 0.200–1.905 | 0.398 |        |         |
|                | Advance    | 18            | 150                 | Reference             |            |        |         |
| TNM Stage      | I-II       | 6             | 105                 | 0.354                 | 0.133–0.939 | 0.031 | 1.675 | 0.496–5.660 | 0.406 |
|                | I          | 16            | 99                  | Reference             | Reference |        |         |

NRS 2002: nutrition risk screening 2002; BMI: body mass index; LSMM: low skeletal muscle mass
### Impact of LSMM on 1-, 3-year OS

The median follow-up time of the entire matched cohort was 36 months (range 0–45 months). There are 65 deaths. The 3-year OS rates was 71.24% for all patients. The 1-, 3-year OS rates were 83.2%, 64.6% respectively, for patients with LSMM and 92.9%, 77.9%, respectively, for those non-LSMM. The survival curves for patients of GC with and without LSMM are shown in Fig. 2. Patients with LSMM showed a significantly poorer OS than the non-LSMM group ($P = 0.016$, Fig. 2a).

After stratification based on the pT stage of the tumor, the 3-year OS rate of the early GC cohort was 89.66%, and no statistically significant difference in the 3-year OS rates between the LSMM (3-year OS, 85.16%) and non-LSMM (3-year OS, 93.55%) were found ($P = 0.286$, Fig. 2b). However, the 3-year OS rate of the advance GC cohort was 64.89%, and statistically significant difference in the 3-year OS rates between the two groups were observed (58.14% vs 71.95%, $P = 0.034$, Fig. 2c).

### Discussion

Our study used a propensity score-matched analysis to reduce selection biases. This more scientific and rigorous analysis provided more reliable evidence. The results of the study demonstrated that the 3-year OS rate of patients with LSMM was 64.6%, which was significantly poorer than those with non-LSMM (77.9%) ($P = 0.016$) and that LSMM was an independent risk factor for overall survival in patients with GC. Furthermore, preoperative LSMM may be particularly useful in advance GC. However, the results in our study showed that LSMM is not associated with the incidence of postoperative complications.
Several clinical studies have reported that LSMM might be an unfavorable factor for the short-time outcomes and prognosis\cite{15–18}, but some existing have shown contrasting results\cite{19–22}. Katsunobu et al.\cite{19} have shown that there is no relationship between preoperative LSMM and postoperative complications. Kuroki, L. M. et al.\cite{21} also indicate that LSMM has no negative impact on postoperative complications or overall survival among endometrial cancer patients. The different conclusions may be due to: 1. Different studies have different diagnostic criteria for low skeletal muscle mass; 2. Different tumor types may lead to different conclusions; 3. Different treatment methods; 4. Different races. In our hospital, laparoscopic gastrectomy accounts for more than 80% of gastric cancer operations. Therefore, we only included patients who underwent laparoscopic gastrectomy. In this study, the diagnostic criteria for LSMM came from a research based on Asian populations, which is suitable for the included population. In addition, the application of PSM analysis makes the research conclusions more reliable. Skeletal muscle mass is an excellent indicator for assessing the physical condition, and it is more objective to reflect the nutritional status of the body than Body Mass Index (BMI).

The reason why people pay attention to skeletal muscle mass is that the change of skeletal muscle mass is closely related to the postoperative outcome. For those patients with severe skeletal muscle depletion before surgery, clinicians should comprehensively evaluate and formulate more scientific treatment strategies, such as nutritional support treatment\cite{23, 24}. Studies have shown that nutritional support program and exercise are effective way to improve postoperative outcomes in patients with GC\cite{25}.

In this study, we divided patients into early stage and advanced stage GC for analysis. The results showed that there was significant difference in 3-year OS between the LSMM group and the non-LSMM group in advanced GC ($P = 0.0343$), but no difference was found in early GC (3-year OS, 85.16% vs 93.55%, $P = 0.2864$). The initial hypothesis of the study was that the two groups can show differences in early and advanced GC. This is an interesting discovery, and no relevant research has been reported so far. We will continue to follow up these patients to further observe the impact of LSMM on the prognosis of patients with early GC.

CT is a routine examination for patients with GC before surgery, so it is feasible to use CT to assess skeletal muscle mass. It will not bring additional economic burden to patients. This study is a single-center retrospective study. The main purpose is to clarify the relationship between preoperative skeletal muscle mass and prognosis in patients with GC. CT was used to assess the preoperative skeletal muscle mass and found high-risk patients. This is of great significance to the scientific diagnosis and treatment of GC patients.

There are some potential limitations in this study. This study is a retrospective single-center study, the data integrity may be insufficient. We plan to conduct a prospective study to further explore the adverse effects of LSMM.

### Conclusions

By using PSM analysis to balance the differences between cofounding variables, the study has proved that LSMM is an unfavorable factor for OS rates, especially in patients with advance GC. However, LSMM is not associated with postoperative complications.

### Abbreviations
GC: gastric cancer; LSMM: low skeletal muscle mass; BMI: body mass index; NRS 2002: nutrition risk screening 2002; PMI: psoas muscle index; WBC: white blood cell; TNM: tumor node metastasis; AJCC: American joint committee on cancer; PSM: Propensity score matching.

Declarations

Acknowledgements: Not applicable.

Author Contributions: Zhen Fang, Peijuan Li, conceptualization, methodology, data curation, writing-original draft preparation; Jin Liu, data curation, software, investigation; Wei Chong, software, investigation; Fengying Du, Hao Wu, Yang Liu, methodology; visualization; Jiongdi Lu, methodology; Liang Shang, Fei Li, supervision, project administration; Leping Li, supervision, project administration, funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Key Research and Development Program of Shandong Province (No.2019JZZY010104; No.2019GSF108146); Special Foundation for Taishan Scholars Program of Shandong Province (No.ts20190978); Academic promotion programme of Shandong First Medical University (No. 2019QL021).

Availability of data and materials: All the data and material are available.

Ethics Approval: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Shandong Provincial Hospital Shandong Provincial Hospital (LCYJ: NO.2019-025)

Consent for publication: Approved.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
2. Sano T. Gastric cancer: Asia and the world. Gastric Cancer. 2017;20:1–2.
3. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.
4. Nishigori T, Obama K, Sakai Y. Assessment of body composition and impact of sarcopenia and sarcopenic obesity in patients with gastric cancer. Transl Gastroenterol Hepatol. 2020;5:22.
5. Lepage C, Sant M, Verdecchia A, Forman D, Esteve J, Faisre J. group Ew: Operative mortality after gastric cancer resection and long-term survival differences across Europe. Br J Surg. 2010;97:235–9.
6. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127:990S–991S.
7. Imai K, Takai K, Watanabe S, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in...
Loss of Skeletal Muscle Volume. *Nutrients* 2017, 9.

8. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *J Clin Oncol.* 2013;31:1539–47.

9. Song EJ, Lee CW, Jung SY, Kim BN, Lee KS, Kang HS, Park IH, Lee MH, Kim YJ, et al. Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer. *Breast Cancer Res Treat.* 2018;172:425–36.

10. Ansari E, Chargi N, van Gemert JTM, van Es RJJ, Dieleman FJ, Rosenberg A, Van Cann EM, de Bree R. Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap. *Oral Oncol* 2020:101–104.

11. Okumura S, Kaido T, Hamaguchi Y, Fujimoto Y, Masui T, Mizumoto M, Hammad A, Mori A, Takaori K, Uemoto S. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. *Surgery.* 2015;157:1088–98.

12. Huang DD, Chen XX, Chen XY, Wang SL, Shen X, Chen XL, Yu Z, Zhuang CL. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study. *J Cancer Res Clin Oncol.* 2016;142:2347–56.

13. Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. *J Natl Cancer Inst* 2017, 109.

14. Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Hammad A, Tamai Y, Inagaki N, Uemoto S. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. *Nutrition.* 2016;32:1200–5.

15. Chen XY, Li B, Ma BW, Zhang XZ, Chen WZ, Lu LS, Shen X, Zhuang CL, Yu Z. Sarcopenia is an effective prognostic indicator of postoperative outcomes in laparoscopic-assisted gastrectomy. *Eur J Surg Oncol.* 2019;45:1092–8.

16. Xiao J, Caan BJ, Cespedes Feliciano EM, Meyerhardt JA, Peng PD, Baracos VE, Lee VS, Ely S, Gologorsky RC, Weltzien E, et al. Association of Low Muscle Mass and Low Muscle Radiodensity With Morbidity and Mortality for Colon Cancer Surgery. *JAMA Surg.* 2020;155:942–9.

17. Iritani S, Imai K, Takai K, Hanai T, Ideta T, Miyazaki T, Suetsumugu A, Shiraki M, Shimizu M, Moriwaki H. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. *J Gastroenterol.* 2015;50:323–32.

18. Bingmer K, Kondray V, Ofshteyn A, Bliggenstorfer JT, Dietz DW, Charles R, Stein SL, Paspulati R, Steinhagen E. Sarcopenia is associated with worse overall survival in patients with anal squamous cell cancer. *J Surg Oncol.* 2020;121:1148–53.

19. Sakurai K, Kubo N, Tamura T, Toyokawa T, Amano R, Tanaka H, Muguruma K, Yashiro M, Maeda K, Hirakawa K, Ohira M. Adverse Effects of Low Preoperative Skeletal Muscle Mass in Patients Undergoing Gastrectomy for Gastric Cancer. *Ann Surg Oncol.* 2017;24:2712–9.

20. Fang Z, Du F, Shang L, Liu J, Ren F, Liu Y, Wu H, Liu Y, Li P, Li L. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications. *Expert Rev Gastroenterol Hepatol.* 2021;15:317–24.
21. Kuroki LM, Mangano M, Allsworth JE, Menias CO, Massad LS, Powell MA, Mutch DG, Thaker PH. Preoperative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer. Ann Surg Oncol. 2015;22:972–9.

22. Rinninella E, Strippoli A, Cintoni M, Raoul P, Vivolo R, Di Salvatore M, Genco E, Manfredi R, Bria E, Tortora G, et al: Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. Nutrients 2021, 13.

23. McGlory C, van Vliet S, Stokes T, Mittendorfer B, Phillips SM. The impact of exercise and nutrition on the regulation of skeletal muscle mass. J Physiol. 2019;597:1251–8.

24. Hammad A, Kaido T, Aliyev V, Mandato C, Uemoto S. Nutritional Therapy in Liver Transplantation. Nutrients 2017, 9.

25. Yamamoto K, Nagatsuma Y, Fukuda Y, Hirao M, Nishikawa K, Miyamoto A, Ikeda M, Nakamori S, Sekimoto M, Fujitani K, Tsujinaka T. Effectiveness of a preoperative exercise and nutritional support program for elderly sarcopenic patients with gastric cancer. Gastric Cancer. 2017;20:913–8.

Figures
Figure 1

Flow diagram describing the patient matching process.
Figure 2

Impact of LSMM on OS. (a) in all patients of GC. The 3-year OS rate was 71.24% for all patients, 64.6% and 77.9% for LSMM and non-LSMM groups respectively (P=0.0158). (b) in the early GC. The 3-year OS rate were 85.16% and 93.55% for the LSMM and non-LSMM groups respectively (P=0.2864). (c) in the advance GC. The 3-year OS rate were 58.14% and 71.95% for the LSMM and non-LSMM groups respectively (P=0.0343).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementFigure1.pptx